

FORM PTO-1449/A and B (Modified)		APPLICATION NO.: 09/804,987	ATTY. DOCKET NO.: M00765.70035.US
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		FILING DATE: March 13, 2001	CONFIRMATION NO.: 9368
		APPLICANT: Waeber et al.	
Sheet	1 of 1	GROUP ART UNIT: 1646	EXAMINER: Li, Ruixiang

U.S. PATENT DOCUMENTS

Examiner's Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or of issue of Cited Document MM-DD-YYYY
		Number	Kind Code		

FOREIGN PATENT DOCUMENTS

Examiner's Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document (not necessary)	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/ Country	Number	Kind Code			

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
RLi	C19	Salomone et al. "Selective Cerebral Vasoconstriction by Sphingosine-1-Phosphate: Mechanism of Action" <i>Soc. Neurosci.</i> 646, 11 Abstract	
	C20	Bischoff et al. "Sphingosine-1-Phosphate and sphingosylphosphorylcholine constrict renal and mesenteric microvessels <i>in vitro</i> ", <i>Br. J. Pharmacol.</i> , 130:1871-1877, 2000	
	C21	Bischoff et al., "Sphingosine-1-Phosphate reduces rat renal and mesenteric blood flow <i>in vivo</i> in a pertussis toxin-sensitive manner", <i>Br. J. Pharmacol.</i> , 130:1878-1883, 2000	
	C22	Ohmori et al., "Sphingosine 1-Phosphate induces contraction of coronary artery smooth muscle cells via S1P ₂ ", <i>Cardio. Res.</i> , 58:170-177, 2003	
	C23	Coussin, et al., "Comparison of Sphingosine 1-Phosphate-Induced Intracellular Signaling Pathways in Vascular Smooth Muscles: Differential Role in Vasoconstriction", <i>Circ. Res.</i> , 91:151-157, 2002	
RLi	C24	Salomone et al., "S1P ₃ receptors mediate the potent constriction of cerebral arteries by sphingosine-1- phosphate", <i>Eur. J. Pharmacol.</i> , 469:125-134, 2003	

EXAMINER Ruixiang Li	DATE CONSIDERED 8/12/2003
-------------------------	------------------------------

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. __, filed __, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE - Must provide a copy of any patent, publication, other information listed, even if it was previously submitted to, or cited by, the U.S. Patent Office in an earlier application, unless the earlier application is identified by the IDS and is relied upon for an earlier filing date under 35 U.S.C. §120, and the copy was provided in the earlier application.]